Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Depreciation & Amortization (CF) (2021 - 2025)

Amylyx Pharmaceuticals has reported Depreciation & Amortization (CF) over the past 5 years, most recently at $100000.0 for Q4 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $100000.0 for Q4 2025, down 50.0% from a year ago — trailing twelve months through Dec 2025 was $500000.0 (down 44.44% YoY), and the annual figure for FY2025 was $500000.0, down 44.44%.
  • Depreciation & Amortization (CF) for Q4 2025 was $100000.0 at Amylyx Pharmaceuticals, roughly flat from $100000.0 in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for AMLX hit a ceiling of $302000.0 in Q3 2023 and a floor of $10000.0 in Q1 2021.
  • Median Depreciation & Amortization (CF) over the past 5 years was $173500.0 (2022), compared with a mean of $151350.0.
  • Biggest five-year swings in Depreciation & Amortization (CF): skyrocketed 1550.0% in 2022 and later crashed 50.0% in 2025.
  • Amylyx Pharmaceuticals' Depreciation & Amortization (CF) stood at $22000.0 in 2021, then soared by 727.27% to $182000.0 in 2022, then soared by 65.38% to $301000.0 in 2023, then crashed by 33.55% to $200000.0 in 2024, then crashed by 50.0% to $100000.0 in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $100000.0 (Q4 2025), $100000.0 (Q3 2025), and $100000.0 (Q2 2025) per Business Quant data.